Mauro Bafutto

Mauro Bafutto

Auto-generated profile, based on publicly available information

Mauro Bafutto

Institute of Gastroenterology and Digestive Endoscopy, Goiânia, Goiás, Brazil

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2020 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
TATursi Antonio
Tursi Antonio
GBGiovanni Brandimarte
Giovanni Brandimarte
FMFrancesco Di Mario
Francesco Di Mario
ALAngel Lanas
Angel Lanas
Carmelo ScarpignatoCarmelo Scarpignato
Carmelo Scarpignato
MWMarjorie Walker
Marjorie Walker
The statements produced by the Chairmen and Speakers of the 3rd International Symposium on Diverticular Disease, held in Madrid on April 11th-13th 2019, are reported. Topics such as current and evolving concepts on the pathogenesis, the course of the disease, the news in diagnosing, hot topics in medical and surgical treatments, and finally, critical issues on the disease were reviewed by the Chairmen who proposed 39 statements graded according to level of evidence and strength of recommendation. Each topic was explored focusing on the more relevant clinical questions. The vote was conducted on a 6-point scale and consensus was defined a priori as 67% agreement of the participants. The voting group consisted of 124 physicians from 18 countries, and agreement with all statements was provided. Comments were added explaining some controversial areas.

1 December 2012 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
MCMichelle Bafutto Gomes Costa
Michelle Bafutto Gomes Costa
IJItaciron Luz Azeredo Jr.
Itaciron Luz Azeredo Jr.
RMRicardo Duarte Marciano
Ricardo Duarte Marciano
LCLuciana Morelli Caldeira
Luciana Morelli Caldeira
MBMauro Bafutto
Mauro Bafutto
CONTEXT: Functional dyspepsia is a condition in which symptoms are not related to organic underlying disease; its pathogenesis is not well known. The small intestinal bacterial overgrowth (SIBO) is characterized by the increase in the number and/or type of colonic bacteria in the upper gastrointestinal tract. The hypothesis of SIBO being associated to functional dyspepsia must be considered, since the impaired motility of the gastrointestinal tract is one of the main etiologic factors involved on both pathologies. OBJECTIVE: To determine if there is SIBO in patients with functional dyspepsia. METHODS: Case-control study, evaluating 34 patients: 23 functional dyspeptic and 11 non-dyspeptic (control group). Questionnaire applied based on Rome III criteria. The patients underwent H2-lactulose breath test, considered positive when: H2 peak exceeding 20 ppm, in relation to fasting, or two peaks exceeding 10 ppm sustained until 60 minutes. RESULTS: Of the 23 dyspeptic patients, 13 (56.5%) obtained positive results for SIBO trough the H2-lactulose breath test. On control group, SIBO was not observed. The association between the dyspeptic group and the control group regarding SIBO was statistically significant, with P = 0.0052. In the group of dyspeptic patients, 12 (52.2%) were using proton pump inhibitor; of these 9 (75%) were positive for SIBO. In the control group, none of the 11 patients used proton pump inhibitors and SIBO was not observed. The association of the dyspeptic group using proton pump inhibitor that were positive for SIBO and the control group was statistically significant, with P = 0.0011. CONCLUSION: It was found that, patients with functional dyspepsia presented SIBO, when they underwent to H2-lactulose breath test, compared to the non-dyspeptic. In addition, it was observed a higher prevalence of SIBO in dyspeptic patients that were using proton pump inhibitors, compared to control group.

1 March 2011 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
MBMauro Bafutto
Mauro Bafutto
JAJosé Roberto de Almeida
José Roberto de Almeida
NLNayle Vilela Leite
Nayle Vilela Leite
EOEnio Chaves Oliveira
Enio Chaves Oliveira
SGSalustiano Gabriel-Neto
Salustiano Gabriel-Neto
JRJoffre Rezende-Filho
Joffre Rezende-Filho
CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome patients are still unknown. OBJECTIVE: To observe the effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients. METHODS: Based on Rome III criteria, 61 irritable bowel syndrome with diarrhea patients (18 years old or more) were included in the evaluation. Patients were divided into two groups: postinfectious irritable bowel syndrome group, with 18 patients medicated with mesalazine 800 mg 3 times a day for 30 days; noninfective irritable bowel syndrome group, with 43 patients medicated with mesalazine 800 mg 3 times a day for 30 days. Symptom evaluations at baseline and after treatment were performed by means of a four-point Likert scale including stool frequency, stool form and consistency (Bristol Stool Scale), abdominal pain and distension (maximum score: 16; minimum score: 4). RESULTS: Postinfectious irritable bowel syndrome group presented a statistically significant reduction of the total symptom score (P

1 December 2013 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
MBMauro Bafutto
Mauro Bafutto
JAJosé Roberto de Almeida
José Roberto de Almeida
NLNayle Vilela Leite
Nayle Vilela Leite
MCMichelle Bafutto Gomes Costa
Michelle Bafutto Gomes Costa
EOEnio Chaves de Oliveira
Enio Chaves de Oliveira
JRJoffre Resende-Filho
Joffre Resende-Filho
ContextIrritable bowel syndrome (IBS) is a functional bowel disease characterized by abdominal pain and altered intestinal habits. The pathophysiology of IBS remains unclear. Recent studies have demonstrated that some IBS patients, especially in diarrhea-predominant IBS (IBS-D), display persistent signs of minor mucosal inflammation and a modified intestinal microflora. The mesalazine has known intestinal anti-inflammatory properties. Saccharomyces boulardii is a probiotic used for a long time in treatment of diarrhea, including infectious diarrhea.ObjectiveEvaluate the effects of mesalazine alone, combined therapy of mesalazine with liophylised Saccharomyces boulardii or alone on symptoms of IBS-D patients.MethodsBased on Rome III criteria, 53 IBS-D patients (18 year or more) were included. To exclude organic diseases all patients underwent colonoscopy, stool culture, serum anti-endomisium antibody, lactose tolerance test and ova and parasite exam. Patients were divided in three groups: mesalazine group (MG) - 20 patients received mesalazine 800 mg t.i.d. for 30 days; mesalazine and Saccharomyces boulardii group (MSbG) - 21 patients received mesalazine 800 mg t.i.d. and Saccharomyces boulardii 200 mg t.i.d. for 30 days and; Saccharomyces boulardii group (SbG) – 12 patients received Sb 200 mg t.i.d. for 30 days. Drugs that might have any effect on intestinal motility or secretion were not allowed. Symptom evaluations at baseline and after treatment were performed by means of a 4-point likert scale including: stool frequency, stool form and consistency (Bristol scale), abdominal pain and distension. Paired t test and Kruskal-Wallis test were used for statistical analyses.ResultsCompared to baseline, there were statistically significant reduction of symptom score after 30 th day therapy in all three groups: MG (P<0.0001); MSbG (P<0.0001) and in SbG (P= 0.003). There were statistically significant differences in the symptom score at 30 th day therapy of the MG, MSbG and SbG groups (P = 0.03). There were no statistical differences between MSbG and MG symptom score at 30th day therapy (P = 0.9).ConclusionsThe use of mesalazine alone, Saccharomyces boulardii alone or combined treatment with mesalasine andSaccaromyces boulardii improved IBS-D symptoms. The improvement of the symptom score was greater with mesalazine alone or combined with Sb as compared with Sb treatment alone. These preliminary results suggest that mezalazine may be useful in treatment of IBS-d patients, and warrant further larger studies.

1 January 2020 in Gastroenterology Research
Verified
Journal Article
Open access
PDF file
MBMauro Bafutto
Mauro Bafutto
EOEnio Chaves Oliveira
Enio Chaves Oliveira
JFJoffre Rezende Filho
Joffre Rezende Filho
Use of Vitamin D With Anti-Tumor Necrosis Factor Therapy for Crohn’s Disease

21 February 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RFRenata de Sá Brito Fróes
Renata de Sá Brito Fróes
AAAdriana Ribas Andrade
Adriana Ribas Andrade
MFMikaell Alexandre Gouvea Faria
Mikaell Alexandre Gouvea Faria
HSHeitor S De Souza
Heitor S De Souza
RPRogerio Serafim Parra
Rogerio Serafim Parra
RSRogerio Saad-Hossne
Rogerio Saad-Hossne
The Brazilian Organization for Crohn's Disease and Colitis (GEDIIB) established a national registry of inflammatory bowel disease (IBD). The aim of the study was to identify clinical factors associated with disease severity in IBD patients in Brazil. A population-based risk model aimed at stratifying the severity of IBD based on previous hospitalization, use of biologics, and need for surgery for ulcerative colitis (UC) and Crohn’s Disease (CD) and on previous complications for CD. A total of 1179 patients (34.4 ± 14.7y; females 59%) were included: 46.6% with UC, 44.2% with CD, and 0.9% with unclassified IBD (IBD-U). The time from the beginning of the symptoms to diagnosis was 3.85y. In CD, 41.2% of patients presented with ileocolic disease, 32% inflammatory behavior, and 15.5% perianal disease. In UC, 46.3% presented with extensive colitis. Regarding treatment, 68.1%, 67%, and 47.6% received biological therapy, salicylates and immunosuppressors, respectively. Severe disease was associated with the presence of extensive colitis, EIM, male, comorbidities, and familial history of colorectal cancer in patients with UC. The presence of Montreal B2 and B3 behaviors, colonic location, and EIM were associated with CD severity. In conclusion, disease severity was associated with younger age, greater disease extent, and the presence of rheumatic EIM.